Sara M. Nolte
Sara Nolte holds a Bachelor of Health Sciences and Masters of Science in Biochemistry & Biomedical Sciences from McMaster University. Her MSc research focused on developing of cancer stem model to study brain metastases from the lung. She then spent a year working on developing cell-based cancer immunotherapies. Throughout a highly productive graduate career, Sara became interested in scientific communication and education. She is now involved in developing undergraduate programs and courses in the health sciences at McMaster, and is looking for ways to improve scientific communication with the public. Outside of science, Sara enjoys participating in a variety of sports, and is a competitive Olympic weightlifter hoping to compete at the National level soon!
Posts by: Sara M.
With the start of a new year, I like to take a moment to think about what things in cancer research got me really excited the previous year. Beyond a doubt, that thing for me in 2017 was the first (and second!) FDA approval of a CAR T-cell (chimeric antigen receptor T-cell) therapy as a […]
Over two years ago, an article published in Science took the Internet and media by storm. The paper, “Variation in cancer risk among tissues can be explained by the number of stem cell divisions,” better known as “The ‘Bad Luck’ Cancer Study,” used mathematical modeling to demonstrate that most cancers were a result of chance […]
On November 15th, my social media pages exploded with posts and comments regarding the latest news about how the gene-editing ‘CRISPR-Cas9’ technology had been used in the first human patient. The article, published by Nature, was entitled “CRISPR gene-editing tested in a person for the first time.” It described how a group of Chinese scientists […]
. Much of what we discuss here on Signals is what’s going on in the lab. I’ve definitely done my share of promoting basic science research in the cancer stem cell field (here and here). By now you, and almost everyone else, must be wondering why these “wonder drugs” aren’t being used yet. Well, it […]